DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20191097

Efficacy and safety of bromocriptine quick release as an add on therapy with metformin and glipizide in type 2 diabetes mellitus patients: an open label randomized controlled study

Nithyapriya M., S. Purushotaman

Abstract


Background: Type 2 Diabetes Mellitus (DM) is a metabolic disorder, treated by insulin and oral hypoglycaemic agents (OHA). Despite treatment, to protect diabetic population from its complications is difficult. So, there is a need for an OHA with different mechanism of action and minimal side effects. Bromocriptine Mesylate QR (Quick release) formulation was approved by FDA for treatment of type 2 DM. Hence, this study was planned to highlight the usefulness of Bromocriptine QR in type 2 diabetes mellitus.

Methods: Total 140 patients with type 2 DM were randomized into two groups. The control group was treated with Metformin 500 mg BD (twice daily) and Glipizide 5 mg BD for a period of 3 months. The study group received Bromocriptine quick release 1.6 mg once daily, metformin 500 mg BD and Glipizide 5 mg BD for a period of 3 months. In both control and study groups, fasting blood glucose, postprandial blood glucose was monitored at 0, 1st, 2nd and 3rd month. HbA1C was done at baseline and at the end of 3 months.

Results: There was statistically significant decrease in fasting blood glucose, postprandial blood glucose and HbA1C when compared to baseline in both control group (p <0.05) and study group (p <0.05) at the end of 3 months. But the decrease in FBS, PPBS, HbA1C was higher in the study group (p=0.0001) than the control group (p=0.001).

Conclusions: In type 2 DM patients, Bromocriptine QR, combined with metformin and Glipizide reduced fasting and postprandial blood glucose and HbA1C significantly compared to metformin and glipizide alone.

Keywords


Bromocriptine, Glipizide, Metformin, Type 2 diabetes mellitus

Full Text:

PDF

References


Ryan JG. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. Gender Med. 2009;6:86-108.

Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90(1):501-6.

Deleu D, Northway MG, Hanssens Y. An evidence-based review of dopamine receptor agonists in the treatment of Parkinson's disease. Saudi Med J. 2002;23(10):1165-75.

Mahajan R. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Ind J Pharmacol. 2009;41(4):197.

Kerr JL, Timpe EM, Petkewicz KA. Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Ann Pharmacotherapy. 2010;44(11):1777-85.

Via MA, Chandra H, Araki T, Potenza MV, Skamagas M. Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes. Diab Metab Syndrome Obes Targets Therapy. 2010;3:43.

DeFronzo RA. Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diab Care. 2011;34(4):789-94.

Dowse G, Zimmet P. The thrifty genotype in non-insulin dependent diabetes. BMJ. 1993;306(6877):532.

Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opinion Investigational Drugs. 1999;8(10):1683-707.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diab Care. 2000;23(8):1154-61.

Aminorroaya A, Janghorbani M, Ramezani M, Haghighi S, Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics?. Hormone Res Paediatrics. 2004;62(2):55-9.

Scranton R, Cincotta A. Bromocriptine–unique formulation of a dopamine agonist for the treatment of type 2 diabetes. Expert Opinion Pharmacotherapy. 2010;11(2):269-79.

Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diab Care. 1996;19(6):667-70.

Ghosh A, Sengupta N, Sahana P, Giri D, Sengupta P, Das N. Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial. Ind J Pharmacol. 2014;46(1):24.

Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Ind J Endocrinol Metab. 2011;15(1):17.

American Diabetes Association. Standards of medical care for diabetes. Diab Care. 2008;31(1):S12-54.

Książek A, Załuska W. Sympathetic overactivity in uremia. J Renal Nutrition. 2008;18(1):118-21.

Kagan A, Gertler A, Ulman M, Bar-Khayim Y. Serum levels and peritoneal loss of prolactin in CAPD patients. In: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 1991; 7: 247-252.

Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, et al. Brain dopamine and obesity. Lancet. 2001;357(9253):354-7.

Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diab Care. 2000;23(8):1154-61.

Ramteke KB, Ramanand SJ, Ramanand JB, Jain SS, Raparti GT, Patwardhan MH, et al. Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes. Ind J Endocrinol Metab. 2011;15(1):S33.

Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven GM, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diab Care. 1997;20(11):1697-701.